Emideltide
Pending PCACAlso known as: DSIP, Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Sleep & NeurologicalLast reviewed: April 28, 2026
A nonapeptide (9 amino acids) first isolated from rabbit cerebral venous blood in 1977. Originally studied for sleep-induction properties, it is now being investigated for opioid withdrawal and chronic insomnia.
Mechanism of Action
Modulates the sleep-wake cycle through interactions with opioid, serotonin, and other neurotransmitter systems. Reduces the activity of stress-response systems. Mechanism is not fully characterized, but effects appear to be on circadian regulation and stress adaptation.
Common Uses
- Sleep quality improvement
- Opioid withdrawal support
- Stress and cortisol reduction
- Chronic insomnia
- Narcolepsy (investigational)
Known Risks
- Limited human clinical data
- Mechanism not fully understood
- Potential interactions with opioid medications
- Inconsistent results across studies
- Long-term effects unknown
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026 for opioid withdrawal, chronic insomnia, and narcolepsy indications. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
Get notified when the PCAC decides on Emideltide
Scheduled review: July 24, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–300 mcg
Frequency
Once daily before bed
Cycle Length
2–4 weeks
Inject 30–60 minutes before sleep. Effects on sleep quality are variable — some users report significant improvement, others minimal effect. Often used short-term for sleep reset.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.